Diallyl Disulfide Inhibits Breast Cancer Stem Cell Progression and Glucose Metabolism by Targeting CD44/PKM2/AMPK Signaling
Xinhua Xie(Sun Yat-sen University), Xiaoming Xie(Nanchang University), Lu Yang(Hainan Medical University), Hailin Tang(Sun Yat-sen University), Zhi Tian(University of South Florida), Feng Ye(Capital Medical University), Xiaofang Xie(State Administration of Traditional Chinese Medicine of the People's Republic of China), Xiaojia Huang(Sun Yat-sen University), Cheng Peng(Shandong First Medical University), Xiaofang Guo(Sun Yat-sen University)
Cited by 40
Related Papers
Asymmetric organocatalysis: an enabling technology for medicinal chemistry
|Chemical Society Reviews|2021|402
Recent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials
|Signal Transduction and Targeted Therapy|2023|364
Single-cell Stereo-seq reveals induced progenitor cells involved in axolotl brain regeneration
|Science|2022|306
circKIF4A acts as a prognostic factor and mediator to regulate the progression of triple-negative breast cancer
|Molecular Cancer|2019|225
N6-methyladenosine regulated FGFR4 attenuates ferroptotic cell death in recalcitrant HER2-positive breast cancer
|Nature Communications|2022|214